The prognosis of acute kidney injury (AKI) in ICU patients might be indicated by levels of a complement factor B fragment.

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced interim results from a Phase 1/2a clinical study of ARO-CFB, the company’s investigatio ...

Omeros reports that narsoplimab has not raised any notable safety issues across all clinical studies. For the treatment of TA ...